Shaperon to Conduct Strategic Partnering and Institutional Investor Meetings at the 10th Annual BFC Healthcare Business Development & Investment Conference in Shanghai
May 01 2024 - 11:47AM
Business Wire
Shaperon, Inc. (Kosdaq: 378800), a biotechnology company
dedicated to developing innovative immunology and immuno-oncology
drugs, announced it had been invited by BFC Group to participate in
the upcoming 10th Annual BFC Healthcare Business Development &
Investment Conference. Scheduled to take place in Shanghai, China,
this prestigious event will provide a platform for extensive
business collaboration and investment opportunities in the
expansive pharmaceutical and biotech sector. Shaperon plans to have
meetings with top pharmaceutical and biotech companies in China and
in the world during the event this year.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240501843931/en/
Shaperon to Conduct Strategic Partnering
and Institutional Investor Meetings at the 10th Annual BFC
Conference in Shanghai, China. (Graphic: Business Wire)
Shaperon is actively seeking to broaden its international
presence. The company aims to secure licensing partners, attract
potential strategic and institutional investors, and explore new
business collaborations, particularly within the dynamic Chinese
market. As part of its strategy, Shaperon has planned thirty
partnering meetings with leading pharmaceutical and biotech
companies in China to discuss licensing out opportunities for its
innovative pipelines.
Janice Marie McCourt, CEO of Hudson Therapeutics, Inc., the US
subsidiary of Shaperon, expressed enthusiasm about the seminar and
the scheduled business meetings, stating, "Participating in the
10th BFC Seminar marks a significant milestone for Shaperon.
Following our expansion into the global arena and the establishment
of Hudson Therapeutics in the USA, we have actively extended our
outreach beyond Korea. We have recently completed enrollment for
cohort one in the Phase 2b clinical trial in the US of our atopic
dermatitis treatment, ‘Nugel,’. This conference not only allows us
to showcase our advanced biomedical innovations but also perfectly
aligns with our strategy to penetrate Asian markets, especially
China, where there is a rapidly growing demand for advanced
healthcare solutions."
ABOUT SHAPERON
Shaperon is a clinical stage biotech company developing novel
inflammasome inhibitors. Its unique mechanism of action of
GPCR19-P2X7 modulation suppresses a broad spectrum of inflammatory
cytokines including IL-1β, IL-18, IL-6, and TNF-α by controlling
both priming and activation phase of inflammasome, whereas
conventional approaches are designed to suppress only the
activation phase. With this unique and novel modality which is best
suited to address complex immune-mediated inflammatory disorders,
Shaperon is currently developing multiple clinical programs in
atopic dermatitis, Alzheimer’s disease, and COVID 19 pneumonia in
addition to pre-clinical pipelines, including MASH and obesity
programs.. Shaperon is also developing its immuno-oncology
pipelines, such as bi-specific and tri-specific nanobodies based on
its propritory nanobody platform technology.
ABOUT Hudson Therapeutics
Hudson Therapeutics, a US subsidiary of Shaperon was founded and
incorporated in the US in 2023 to lead global clinical trials,
investor relations, commercial strategy, and business development
of assets from Shaperon. Hudson also plans to develop Shaperon's
early-stage assets in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501843931/en/
Ellie Jung ellie@hudsontherapeutics.com